welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Becker Muscular Dystrophy – A Natural History Study to Predict Efficacy of Exon Skipping
study id #: NCT01539772
condition: Becker Muscular Dystrophy
status: active, not recruitingpurpose:
This is a multi-center natural history study that will be conducted at participating centers in the Cooperative International Neuromuscular Research Group (CINRG). Following a baseline evaluation, participants will have three follow-up visits over a three-year period. The investigators will characterize the Becker muscular dystrophy phenotype, and correlate specific abnormal dystrophin proteins with the range of clinical outcomes.
mechanism of action: Exon-skipping to promote dystrophin production
last updated: November 22, 2018
start date: April 2012
estimated completion: August 2018
size / enrollment: 85
We will utilize the Cooperative International Neuromuscular Research group (CINRG) network to collect cohorts of Becker muscular dystrophy (BMD) patients with in-frame deletions in the dystrophin gene. We will collect clinical data across multiple body systems and correlate these findings to the high-resolution deletion break-point mapping performed from the tissue samples. We will investigate the observed variability to deepen our understanding of molecular mechanisms relevant to the optimization of exon skipping therapeutic approaches.
- Strength and function [Time Frame: Annual]
- Quality of life [Time Frame: Annual]
These questionnaires include:
• Pediatric Quality of Life Inventory (PedsQL)
• Pediatrics and Adult Neuromuscular module Quality of Life (NeuroQOL)
- Medical history assessment - ambulation status, medication history, hospitalizations, surgeries, nutrition, fractures, and cardiac tests [Time Frame: Annual]
• Age 4 or older
• Diagnosis of BMD with an in-frame deletion in the dystrophin gene, where the boundaries of the mutations are confirmed.
Investigator assessment of inability to comply with protocol
Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy ProgramSarepta Therapeutics, Inc., the leader i...
An open-label extension study for patients with Duchenne muscular dystrophy who participated in studies of SRP-5051The purpose of this extension study is t...
PhaseOut DMD: a Phase 2, proof of concept, clinical study of utrophin modulation with ezutromidThis study investigates the hypothesis t...
A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of the study is to see wheth...
State-of-the-art advances in Duchenne muscular dystrophyDuchenne muscular dystrophy (DMD) is a s...
Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystr...Sarepta Therapeutics, Inc., a commercial...
ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystr...ReveraGen BioPharma, Inc. today announce...